DocSym
β
Searchsearch
Search
(G37.3) Acute transverse myelitis in demyelinating disease of central nervous system
More details coming soon
549 735 in individuals diagnosis acute transverse myelitis in demyelinating disease of central nervous system confirmed
10 580 deaths with diagnosis acute transverse myelitis in demyelinating disease of central nervous system
2% mortality rate associated with the disease acute transverse myelitis in demyelinating disease of central nervous system
Diagnosis acute transverse myelitis in demyelinating disease of central nervous system is diagnosed Women are 28.32% more likely than Men
197 036
Men receive the diagnosis acute transverse myelitis in demyelinating disease of central nervous system
5 942 (3.0 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
352 699
Women receive the diagnosis acute transverse myelitis in demyelinating disease of central nervous system
4 638 (1.3 %)Died from this diagnosis.
Risk Group for the Disease acute transverse myelitis in demyelinating disease of central nervous system - Men aged 30-34 and Women aged 35-39
In Men diagnosis is most often set at age 0-84
Less common in men the disease occurs at Age 85-95+Less common in women the disease occurs at Age 90-95+
In Women diagnosis is most often set at age 0-89
Disease Features acute transverse myelitis in demyelinating disease of central nervous system
Absence or low individual and public risk
Acute transverse myelitis in demyelinating disease of central nervous system - what does this mean
Acute transverse myelitis in demyelinating disease of the central nervous system is a condition which is caused by inflammation of the spinal cord, resulting in damage to the myelin sheath that covers and insulates nerve fibers. this damage can lead to a wide range of symptoms, including pain, muscle weakness, and sensory disturbances.
What happens during the disease - acute transverse myelitis in demyelinating disease of central nervous system
Acute transverse myelitis is a demyelinating disease of the central nervous system caused by inflammation of the spinal cord. it is believed to be caused by an autoimmune reaction, in which the body's own immune system mistakenly attacks the myelin sheath, the protective covering of the nerve fibers. this damage to the myelin sheath disrupts the communication between the brain and the rest of the body, resulting in a range of neurological symptoms, including pain, weakness, paralysis, and sensory disturbances.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Complete neurologic examination
- MRI of the spine
- Lumbar puncture and cerebrospinal fluid analysis
- Blood tests (including complete blood count, erythrocyte sedimentation rate, and antinuclear antibody test)
- Electroencephalogram
- Evoked potentials
- Viral serology
- Neuropsychological testing
Treatment and Medical Assistance
Main goal of the treatment: To reduce inflammation and improve neurological function
- Administering corticosteroids to reduce inflammation
- Administering intravenous immunoglobulin to reduce inflammation
- Administering plasma exchange to reduce inflammation
- Physical therapy to improve strength and mobility
- Occupational therapy to improve daily functioning
- Speech therapy to improve communication
- Cognitive therapy to improve thinking and memory
- Psychotherapy to reduce stress and anxiety
16 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Acute transverse myelitis in demyelinating disease of central nervous system - Prevention
The best way to prevent acute transverse myelitis in demyelinating disease of the central nervous system is to maintain a healthy lifestyle, including regular exercise, a balanced diet, and stress management. additionally, avoiding exposure to environmental toxins, such as cigarette smoke, can reduce the risk of developing the disease. vaccinations, such as the flu shot, can also help prevent the disease.